The HPO axis — and the peptides that regulate it

The architecture, once described, has a certain mechanical elegance. Neurons in the hypothalamus — a small cluster called the GnRH pulse generator — synthesize gonadotropin-releasing hormone and release it in pulses into the hypophyseal portal circulation, the private bloodstream that connects hypothalamus to pituitary. The pulses matter; this is not continuous release. The pituitary is, in a sense, listening for a rhythm. When GnRH arrives in pulses at the appropriate frequency and amplitude, gonadotrope cells in the anterior pituitary respond by releasing luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH and FSH enter the systemic circulation and travel to the gonads. In women, FSH drives follicular development in the ovary and the production of estrogen; LH triggers ovulation and the formation of the corpus luteum, which produces progesterone. The rising estrogen and progesterone signal back to the hypothalamus and pituitary, reducing GnRH pulse frequency and suppressing LH and FSH — the negative feedback that prevents runaway stimulation. At the mid-cycle LH surge, the feedback briefly reverses — positive feedback from rising estrogen amplifies LH release — which is what drives ovulation. Then the corpus luteum forms, progesterone rises, and negative feedback reestablishes control.

In men, the same architecture applies: GnRH drives LH and FSH from the pituitary, LH stimulates Leydig cell testosterone production in the testes, FSH supports Sertoli cell function and spermatogenesis, and testosterone feeds back to suppress GnRH and LH. The HPO label conventionally refers to the female axis but the hypothalamic-pituitary-testicular axis operates by the same principles.

The leuprolide paradox is one of the most instructive examples in endocrine pharmacology. Leuprolide is a GnRH agonist — a synthetic GnRH analog with higher potency and longer half-life than the natural hormone. Given as a single pulse, leuprolide stimulates LH and FSH release exactly as endogenous GnRH does. Given continuously — as it is when delivered by depot injection or implant — it does the opposite. Sustained, nonpulsatile GnRH receptor stimulation downregulates the receptor, exhausts the pituitary's responsiveness, and produces profound gonadotropin suppression. LH and FSH collapse. Testosterone in men falls to castrate levels. Estrogen in women falls to post-menopausal levels. This is the pharmacological action used in prostate cancer treatment, endometriosis, precocious puberty, and chemical castration protocols. The same molecule that activates the axis when given as a pulse suppresses the axis when given continuously. Pulsatility is not a detail; it is the mechanism.

The upstream architecture of the GnRH pulse generator was rewritten in the 2000s by a series of discoveries converging on a single neuronal population in the arcuate nucleus of the hypothalamus. These neurons — called KNDy neurons for the three neuropeptides they co-express — are the conductors of the GnRH pulse generator. The neuropeptides are kisspeptin, neurokinin B, and dynorphin, and together they regulate each other in a feedback loop that drives the pulsatile pattern of GnRH release. Kisspeptin, acting on the GnRH neuron through the KISS1R receptor, is the most direct stimulator: kisspeptin release triggers a GnRH pulse. Neurokinin B stimulates kisspeptin release from the KNDy neuron itself, sustaining the pulse. Dynorphin provides the counter-signal, inhibiting kisspeptin release and terminating the pulse. The interplay of these three peptides within the KNDy network generates the rhythmic pattern that the pituitary is waiting for.

The discovery of kisspeptin's role in reproductive axis regulation was one of the most significant findings in reproductive endocrinology in recent decades. It came from a 2003 observation: humans with loss-of-function mutations in KISS1R — the kisspeptin receptor — fail to enter puberty and remain in a prepubertal hormonal state through adulthood. The axis is structurally intact; it simply never receives the kisspeptin signal that would activate it. Conversely, activating mutations in KISS1R produce precocious puberty. The gate for reproductive function is kisspeptin signaling, and kisspeptin neurons are the gatekeepers. This reframing — from GnRH as the top of the hierarchy to kisspeptin as the master upstream switch — reorganized how reproductive endocrinology thinks about the axis and opened new therapeutic approaches.

Kisspeptin-10, the biologically active C-terminal fragment of the kisspeptin-54 peptide, has been studied extensively in clinical research for its capacity to activate the reproductive axis from the top. Administered as a single dose or pulsatile infusion, kisspeptin-10 produces a robust LH and FSH surge in both healthy subjects and in patients with hypothalamic amenorrhea. Research groups at Imperial College London and elsewhere have explored kisspeptin-10 in IVF protocols as a trigger for oocyte maturation — replacing the standard hCG trigger — with early evidence suggesting lower ovarian hyperstimulation syndrome risk. The mechanism is upstream: rather than directly stimulating the LH receptor, kisspeptin-10 activates the patient's own GnRH-LH axis, producing a more physiologically modulated surge. Kisspeptin-10 is a research compound; it is not FDA-approved and not in standard clinical use outside of research settings.

Gonadorelin is synthetic GnRH — the identical sequence to endogenous GnRH — available in compounded formulations for pulsatile administration via subcutaneous pump. The clinical application is direct replacement of the missing signal in hypogonadotropic hypogonadism: patients whose hypothalamus fails to produce adequate GnRH pulses (due to Kallmann syndrome, hypothalamic damage, severe functional suppression, or other causes) can have the GnRH pulse restored by a programmable pump delivering small subcutaneous doses at ninety-minute intervals, mimicking the natural pulse pattern. Pulsatile gonadorelin is the most physiologically faithful approach to treating hypothalamic reproductive failure; it allows fertility by reconstituting the axis rather than bypassing it. FDA-approved gonadorelin formulations exist for diagnostic use; the pulsatile pump application uses compounded gonadorelin. GnRH antagonists, including cetrorelix and ganirelix, work by competitive blockade of the GnRH receptor — they suppress the axis rapidly without the initial stimulation phase of GnRH agonists, which makes them the preferred approach for ovarian stimulation in IVF protocols where premature ovulation must be prevented.

HCG — human chorionic gonadotropin — is structurally homologous to LH and acts at the LH receptor. Its role in IVF is as a trigger for oocyte final maturation, simulating the endogenous LH surge. In men, HCG administered exogenously directly stimulates testicular Leydig cells, driving testosterone production through the same receptor that LH uses. This is why HCG is used in male hypogonadism protocols, particularly when testicular function needs to be preserved or restored. In the context of testosterone replacement therapy, exogenous testosterone suppresses LH — because it completes the negative feedback loop — and testicular testosterone production ceases. HCG substitutes for the absent LH signal and maintains testicular function, testicular size, and fertility potential during TRT. This is the rationale for concurrent HCG use in men who wish to preserve fertility on testosterone replacement. HCG is FDA-approved for specific gonadotropin-deficiency and fertility indications.

Follistatin is an endogenous protein that binds and neutralizes activin, a member of the TGF-beta superfamily that normally suppresses FSH release from the pituitary. Elevated follistatin effectively reduces activin's inhibitory effect and allows greater FSH secretion. Recombinant follistatin has been studied in preclinical and early clinical settings for applications including ovarian reserve preservation and muscle growth (follistatin also inhibits myostatin, a muscle mass suppressor). The research is early; follistatin is not clinically available outside of research settings.

The axis is profoundly sensitive to metabolic and stress signals. This sensitivity is not a flaw but a design feature: reproduction is metabolically expensive, and the body's assessment of whether it can afford that expense passes directly through the HPO axis. The KNDy neurons integrate hormonal signals from across the metabolic landscape. Leptin, produced by adipose tissue, is a permissive signal for the reproductive axis — low body fat → low leptin → reduced kisspeptin signaling → suppressed GnRH pulsatility → menstrual irregularity or loss. This is the mechanism behind functional hypothalamic amenorrhea in low-weight states and in athletes with low energy availability. The condition was historically characterized by its three corners — low energy availability, menstrual disturbance, and low bone density — now formalized as Relative Energy Deficiency in Sport, or RED-S.

Stress activates the HPA (hypothalamic-pituitary-adrenal) axis, driving cortisol and CRH release. CRH directly inhibits GnRH release from the hypothalamus. Endorphins, elevated during chronic stress, also suppress GnRH pulsatility. The mechanism by which severe or prolonged psychological stress suppresses reproductive function is not metaphorical; it runs through direct neuroendocrine inhibition of GnRH. The patient who develops menstrual irregularity during a period of extreme professional stress, weight loss, or overtraining is experiencing a physiologically coherent response — the axis is receiving a signal that conditions are unsuitable for reproduction.

Exercise-induced reproductive axis suppression follows the same logic. High-intensity endurance training, particularly in women with inadequate caloric intake to match expenditure, produces progressive GnRH pulse suppression. The kisspeptin neurons are sensitive to ghrelin (the hunger hormone, which rises in negative energy balance and suppresses kisspeptin), to insulin (low in undernutrition), and to leptin — all of which converge on the axis as readouts of metabolic state. The athlete who trains hard, restricts calories, and loses menstrual function is not broken; her axis is responding appropriately to metabolic signals that in evolutionary context would mean famine. The clinical challenge is convincing the system that conditions have improved, which typically requires a sustained period of adequate energy availability.

Post-cycle therapy — the effort by individuals who have used exogenous androgens to restore endogenous axis function — also maps onto this architecture. Exogenous testosterone or other androgens complete the negative feedback loop and suppress LH, FSH, and ultimately testicular testosterone production. The axis can recover spontaneously when exogenous androgens are withdrawn, but recovery timeline is variable and in some cases prolonged. Protocols using gonadorelin (pulsatile GnRH to re-activate the axis from the hypothalamic level), clomiphene or tamoxifen (selective estrogen receptor modulators that block estrogen's negative feedback at the pituitary), and HCG (direct LH receptor agonism to maintain testicular function during the recovery phase) are commonly used. These protocols represent an attempt to support the axis's recovery; their use should be supervised by a prescribing provider familiar with the relevant endocrinology.

The map this axis provides is one of the most practically useful frameworks in endocrinology. If someone has low LH and low FSH alongside low sex hormones — hypogonadotropic hypogonadism — the problem is at the level of the hypothalamus or pituitary, and the treatment approach is fundamentally different from primary gonadal failure, where LH and FSH are elevated because the pituitary is responding appropriately to absent gonadal feedback. The peptide pharmacology of the axis — kisspeptin upstream, gonadorelin at the hypothalamic level, GnRH antagonists for IVF suppression, HCG for LH receptor agonism — maps directly onto each node in the circuit. Knowing where the disruption is tells you which node requires intervention.

What this gives you when navigating reproductive or endocrine concerns with a specialist is a framework for asking better questions. Where in the axis is the signal failing? Is the problem at the pulse generator, the pituitary's responsiveness, the gonadal response, or the feedback signal? The answer to those questions — which require the right blood panel at the right phase of the cycle, interpreted by someone who understands the axis — determines what therapeutic approach makes sense. The treatment is written in the architecture.